Probiotics for maintenance of remission in ulcerative colitis
The DOI matches its Crossref record.
Abstract
Background Several studies have demonstrated the importance of intestinal bacterial flora in the pathogenesis of inflammatory bowel disease. It has therefore been suggested that modifying the bacterial flora with probiotics will attenuate the inflammatory process and prevent relapses in ulcerative colitis (UC). Aim To evaluate the available evidence on the use of probiotics for the maintenance of remission in UC and to assess the occurrence of adverse events associated with the use of probiotics. Design Systematic review and meta-analysis of randomised controlled trials (RCTs) published between 1966 and October 2009. Methods Data sources were MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Inflammatory Bowel Disease Specialised Register, and reference lists of retrieved articles. We aimed to include trials which compared probiotics with either placebo or other interventions. Data extraction and assessment of methodological quality were performed independently by two reviewers. Results Three RCTs met the inclusion criteria. All three trials compared probiotics with mesalazine and no placebo-controlled studies were identified. Meta-analysis of the results of the three RCTs, which involved 555 patients, showed no statistically significant difference in relapse rates between patients who received probiotics and those who received mesalazine (pooled odds ratio 1.45, 95% CI 0.99 to 2.13). The incidence of adverse events was not statistically significantly different between the probiotic and mesalazine groups (pooled odds ratio 1.21, 95% CI 0.80 to 1.84). Conclusion The available evidence does not demonstrate a statistically significant difference between probiotics and mesalazine for the maintenance of remission in UC. However, two of the included studies had relatively small sample sizes and there is insufficient evidence to make any definite conclusions about the efficacy of probiotics for induction of remission in UC. Further well-designed randomised controlled trials including those that compare probiotics with placebo are needed to investigate whether probiotics are effective for the maintenance of remission in UC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Disease-Specific Alterations in the Enteric Virome in Inflammatory Bowel Disease
Norman, J. M., Handley, S. A., Baldridge, M. T., Droit, L., Liu, C. Y., Keller, B. C., Kambal, A., Monaco, C. L., Zhao, G., Fleshner, P., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.002 · Cited by 1,285
Turner, D., Ruemmele, F. M., Orlanski‐Meyer, E., Griffiths, A. M., de Carpi, J. M., Bronsky, J., Veres, G., Aloi, M., Strisciuglio, C., Braegger, C. P., et al. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002035 · Cited by 481
Feuerstein, J. D., Moss, A. C., & Farraye, F. A. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.018 · Cited by 398
Systematic review with meta-analysis: The efficacy of probiotics in inflammatory bowel disease
Derwa, Y., Gracie, D. J., Hamlin, P. J., & Ford, A. C. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14203 · Cited by 393
Metadata
- Authors
- Naidoo, K., Gordon, M., Fagbemi, A., Thomas, A., & Akobeng, A.
- Venue
- Archives of Disease in Childhood
- Publisher
- BMJ
- Published
- 2010-04
- Volume
- 95
- Issue
- Suppl 1
- Pages
- A55.1-A55
- ISSN
- 0003-9888 (ISSN-L)
- 1468-2044
- OpenAlex
- W2763386424
- Cited by
- 65
- References
- 0
- FWCI
- 1.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Probiotics for maintenance of remission in ulcerative colitis. https://app.cochat.ai/papers/10.1136/adc.2010.186338.123
- The paper
- Naidoo, K., Gordon, M., Fagbemi, A., Thomas, A., & Akobeng, A. (2010). Probiotics for maintenance of remission in ulcerative colitis. Archives of Disease in Childhood. https://doi.org/10.1136/adc.2010.186338.123
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.